Quizartinib (AC220) 化学構造
分子量: 560.67

高品質保証

カスタマーフィードバック(3)

MSDS

製品説明

  • Compare FLT3 Inhibitors
    FLT3製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 Quizartinib (AC220)は、FLT3の強力で選択的な阻害剤で、 FLT3-ITDとFLT3-WT自己リン酸化に作用すると、 IC50がそれぞれ 1.1 nM 、4.2 nMになる。
ターゲット Flt3ITD Flt3wt
IC50 1.1 nM [1] 4.2 nM [1]
In vitro試験 AC220, a unique, potent and selective inhibitor of FLT3, has high affinity for FLT3 with a Kd value of 1.6 nM. AC220 inhibits the autophosphorylation of FLT3 in the human leukemia cell lines MV4-11 which harbor a homozygous FLT3-ITD mutation and is FLT3 dependent, and RS4;11 which expresses wild-type FLT3 with IC50 values of 1.1 nM and 4.2 nM, respectively. AC220 is the most potent cellular FLT3-ITD inhibitor, leading to the most significant inhibition of MV4-11 cell proliferation with IC50 of 0.56 nM compared to all other FLT3 inhibitors whose IC50 values range from 0.87 nM to 64 nM. AC220 has no inhibitory activity against the proliferation of A375 cells which harbor an activating mutation in BRAF and are not FLT3 dependent, indicating a large window between FLT3 inhibition and general cytotoxic effects. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HL60/VCR MUfGeY5kfGmxbjDBd5NigQ>? NUTneGliOC5zLUGwJO69VQ>? M3\pNlMxKG2rbh?= Ml25[Y5p[W6lZYOgeZB1[WunIH;mJJN2[nO2cnH0[ZMhd2ZiQVLDS|Ih[W6mIFHCR2IyKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MnKwNlM6PjdzN{e=
K562/ABCB1 NEHvOllHfW6ldHnvckBCe3OjeR?= M4nYZVAvOS1zMDFOwG0> MlOzN|AhdWmw NH7qVlFmdmijbnPld{B2eHSja3Wgc4Yhe3Wkc4TyZZRmeyCxZjDBRmNIOiCjbnSgRWJESjFiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? NEWybIYzOzl4N{G3Oy=>
8226/MR20  NYf1OoVrTnWwY4Tpc44hSXO|YYm= NEf5b|AxNjFvMUCg{txO M2DDUVMxKG2rbh?= M2OzZ4VvcGGwY3XzJJVxfGGtZTDv[kB{fWK|dILheIV{KG:oIFHCR2czKGGwZDDBRmNDOSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NYfoPJBZOjN7NkexO|c>
K562/ABCG2 NWf0[JJCTnWwY4Tpc44hSXO|YYm= NYLQcYM4OC5zLUGwJO69VQ>? NXTn[FN3OzBibXnu M2ThTYVvcGGwY3XzJJVxfGGtZTDv[kB{fWK|dILheIV{KG:oIFHCR2czKGGwZDDBRmNDOSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MlP2NlM6PjdzN{e=
MCF-7 FLV1000 NYPoWWtwU2mwYYPlJGF{e2G7 M4HKR|DjiJN|MDFCuW0> MoHSOUBucW5? M1nyTYRm[3KnYYPld{BcOTJ3SW2tTWFCWCCyaH;0c4xi[mWuaX7nJI9nKEGEQ1KxJIF1KEmFNUCgc4YhOy5|IN88US=> M4iz[|I{QTZ5MUe3
MCF-7 FLV1000 MXHLbY5ie2ViQYPzZZk> M3K3RVDjiJN|MDFCuW0> NHvpSYU2KG2rbh?= NEGyfHpl\WO{ZXHz[ZMhYzF{NVndMWlCSVBicHjveI9t[WKnbHnu[{Bw\iCDQlPCNkBifCCLQ{WwJI9nKDBwMEeg{txO NIPHO44zOzl4N{G3Oy=>
K562/ABCG2 NUfidVJMS2WubDDWbYFjcWyrdImgRZN{[Xm| M2\ydFAvOS9yLkWvNUDDvU1? MoHIPVYhcA>? NY\tZZJ[e2Wwc3n0bZpmeyCNNU[yM2FDS0d{IHPlcIx{KHSxIH3peI95[W62cn;u[UB1d3CxdHXjZY7DqA>? MoDYNlM6PjdzN{e=
8226/MR20 M3f0eWNmdGxiVnnhZoltcXS7IFHzd4F6ew>? MYqwMlEhyrWP M1nFWFk3KGh? NXjRUppbe2Wwc3n0bZpmeyCNNU[yM2FDS0d{IHPlcIx{KHSxIH3peI95[W62cn;u[UB1d3CxdHXjZY7DqA>? NVTJcnJbOjN7NkexO|c>
HMC1.1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vaTGlEPTB;MUSgcm0> NXL4S4tPOjN2OUezNVc>
HMC1.2 NGP3NGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInIN4VKSzVyPUG3Nlchdk1? MoLhNlM1QTd|MUe=
p815 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HKVGlEPTB;NES1JI5O NWXiWoVoOjN2OUezNVc>
Kasumi-1 NX;6cpBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rjXWlEPTB;M{[gcm0> NXLI[21QOjN2OUezNVc>
M-07e + SCF NWDiNXB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnEelZKSzVyPUe3JI5O NH3GT|czOzR7N{OxOy=>
EOL-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7yTWM2OD1zIH7N NUKwSo86OjN2OUezNVc>
MV4;11 MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13BZmlEPTB:IEGgcm0> M4qyeVI{PDl5M{G3
MOLM14 M3rQZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DxZWlEPTB:IEGgcm0> NXv1eWdKOjN2OUezNVc>
Pat.221 NXvmTI03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTZ5NTDuUS=> MWOyN|Q6PzNzNx?=
Pat.279 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\Ue2lEPTB;M{SzOEBvVQ>? MWWyN|Q6PzNzNx?=
Pat.299 MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTd{NEigcm0> M4joU|I{PDl5M{G3
Pat.305 NIPKVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:0TWM2OD15MEe5JI5O NI\qOYozOzR7N{OxOy=>
Pat.375 M4L3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPMZXlKSzVyPUWwN{BvVQ>? NUTEXlFzOjN2OUezNVc>
Pat.379 MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELscXpKSzVyPUiwOkBvVQ>? NXPZ[29KOjN2OUezNVc>
Pat.368 NG\RZZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;KWFdKSzVyPUK3NFAhdk1? M4j6U|I{PDl5M{G3
Pat.601 M1fITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTFzNUOgcm0> MlPkNlM1QTd|MUe=
HMC1.1 NHnGTGhCeG:ydH;zbZMhSXO|YYm= MkL0TWM2OD1|MTDuUS=> NGnXOo4zOzR7N{OxOy=>
p815 NVTS[otmSXCxcITvd4l{KEG|c3H5 M4XTTGlEPTB;M{SxJI5O MWGyN|Q6PzNzNx?=
Kasumi-1 MnrNRZBweHSxc3nzJGF{e2G7 MnjSTWM2OD14NzDuUS=> M3vsfFI{PDl5M{G3
M-07e + SCF MWrBdI9xfG:|aYOgRZN{[Xl? MUfJR|UxRTd6IH7N NWT0c5A{OjN2OUezNVc>
EOL-1 MoDWRZBweHSxc3nzJGF{e2G7 MV3JR|UxRCBzIH7N MWOyN|Q6PzNzNx?=
MV4;11 M2DGe2Fxd3C2b4Ppd{BCe3OjeR?= M4DsNmlEPTB;MjDuUS=> MoLZNlM1QTd|MUe=
MOLM14 NXHOToRwSXCxcITvd4l{KEG|c3H5 NFi3c3FKSzVyPUOgcm0> MWOyN|Q6PzNzNx?=
GIST822 M4jp[2Fxd3C2b4Ppd{BCe3OjeR?= NVHWPYg6UUN3ME2xNFkhdk1? MXmyN|Q6PzNzNx?=
Pat.368 MmOyRZBweHSxc3nzJGF{e2G7 MYXJR|UxRTJ7OUigcm0> MYiyN|Q6PzNzNx?=
Pat.601 MkfWRZBweHSxc3nzJGF{e2G7 M4jVcmlEPTB;OEe2JI5O MX[yN|Q6PzNzNx?=
MV4-11 M1HUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUm0fFhyPzJiaB?= M1G3V2lEPTB;MD6zJI5O NH\yW5IzOzRzMkmzNS=>
MOLM-14 NHLMdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vYUlczKGh? NYezNldrUUN3ME2wMlEhdk1? NIHuUYwzOzRzMkmzNS=>
SEM-K2 NHzPOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXe3NkBp NFS2bohKSzVyPUCuOEBvVQ>? NV7QSYlPOjN2MUK5N|E>
RS4;11 NGHWXldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3XO|IhcA>? M3;LZmlEPTB-MUCsNFAxKG6P MlH2NlM1OTJ7M{G=
THP-1 NGm4UXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmG0O|IhcA>? NEjXeW1KSzVyPkGwMFAxOCCwTR?= MojRNlM1OTJ7M{G=
MV4-11 M1u3O2Fxd3C2b4Ppd{BCe3OjeR?= MUO4M|I1KGh? NXLMcoNpcW6mdXPld{B{cWewaX\pZ4FvfCCjbnSg[I9{\S2mZYDlcoRmdnRiUFHSVEBkdGWjdnHn[UBidmRiYXPjeY12dGG2aX;uJI9nKHO3Yj2yUkBFVkF? NWXFXmtrOjN2MUK5N|E>
MOLM-14 NFr1W4RCeG:ydH;zbZMhSXO|YYm= Ml7vPE8zPCCq Mmq4bY5lfWOnczDzbYdvcW[rY3HueEBidmRiZH;z[U1l\XCnbnTlcpQhWEGUUDDjcIVifmGpZTDhcoQh[WOldX31cIF1cW:wIH;mJJN2[i1{TjDEUmE> Ml3qNlM1OTJ7M{G=
SEM-K2 NX\teXc{SXCxcITvd4l{KEG|c3H5 NGraUXc5NzJ2IHi= NH;I[2VqdmS3Y3XzJJNq\26rZnnjZY51KGGwZDDkc5NmNWSncHXu[IVvfCCSQWLQJINt\WG4YXflJIFv\CCjY3P1cZVt[XSrb36gc4Yhe3WkLULOJGRPSQ>? MVKyN|QyOjl|MR?=
MV4-11 NGjP[XNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHEO|IhcA>? MnLyTWM2OD1yLkW2JOKyKDBwMzDuUS=> NUDMNYpQOTl4NUS0NFg>
A375 M4jlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVL4N|E1PzJiaB?= NYOzeodnUUN3ME6gNVAhODByIH7N NU[5eFNsOTl4NUS0NFg>

... Click to View More Cell Line Experimental Data

In vivo試験 Oral administration of AC220 (10 mg/kg) induces time-dependent inhibition of FLT3 autophosphorylation in the FLT3-ITD–dependent MV4-11 tumor xenograft mouse model; the inhibition being 90% at 2 hours and 40% at 24 hours. AC220 significantly extends survival in a mouse model of FLT3-ITD AML with doses as low as 1 mg/kg given orally once a day. Treatment with AC220 at 10 mg/kg for 28 days results in rapid and complete regression of tumors in all mice with no tumor regrowth during the 60-day posttreatment period. AC220 displays more significant efficacy compared to sunitinib treatment which causes tumors to shrink slowly and resume growth immediately upon discontinuation of treatment in all but one of the mice. [1]
臨床試験 A Phase I study of AC220 in patients with relapsed/refractory acute myeloid leukemia, regardless of FLT3 status, has been completed.
特集 The most potent cellular FLT3-ITD inhibitor.

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

Inhibition of FLT3 autophosphorylation To measure inhibition of FLT3 autophosphorylation, MV4-11 or RS4;11 cells are cultured in low serum media (0.5% FBS) overnight and seeded at a density of 400 000 cells per well in a 96-well plate the following day. The cells are incubated with different concentrations of AC220 for 2 hours at 37 °C. To induce FLT3 autophosphorylation in RS4;11 cells, 100 ng/mL FLT3 ligand is added for 15 minutes after the 2-hour AC220 incubation. Cell lysates are prepared and incubated in 96-well plates precoated with a total FLT3 capture antibody. The coated plates are incubated with either a biotinylated antibody against FLT3 to detect total FLT3 or an antibody against phosphotyrosines to detect FLT3 autophosphorylation. In both cases, a SULFO-tagged streptavidin secondary antibody is used for electrochemiluminescence detection on the Meso Scale Discovery platform. The concentration of AC220 that inhibits FLT3-ITD or TLT3-WT autophosphorylation by 50% represents IC50 value

細胞アッセイ: [1]

細胞株 MV4-11 and RS4;11 cells
濃度 Dissolved in DMSO, final concentration ~20 μM
反応時間 72 hours
実験の流れ Cells are cultured overnight in low serum media (0.5% FBS), seeded in a 96-well plate at 40 000 cells per well and exposed to AC220 for 72 hours at 37 °C. Cell viability is measured using the Cell Titer-Blue Cell Viability Assa

動物実験: [1]

動物モデル Female NU/NU or severe combined immunodeficient mice implanted with MV4-11 cells
製剤 Formulated in 22% hydroxypropyl-β-cyclodextrin
投薬量 ~10 mg/kg
投与方法 Oral gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Quizartinib (AC220) SDF
分子量 560.67
化学式

C29H32N6O4S

CAS No. 950769-58-1
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 33.2 mg/mL (59.21 mM)
Water <0.3 mg/mL <0.3
Ethanol <0.5 mg/mL <0.5
In vivo 15% Captisol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[4-[7-[2-(4-morpholinyl)ethoxy]imidazo[2,1-b]benzothiazol-2-yl]phenyl]-

文献中の引用 (13)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related FLT3 阻害剤

  • Dovitinib (TKI258) Lactate

    Dovitinib (TKI258) Lactateは一種の「 Dovitinib」の乳酸塩で、一種の多ターゲットRTK阻害剤で、III型(FLT3/c-Kit)に作用する効果が一番強くて、このIC50値が1 nM/2 nMです。同時に、Dovitinib (TKI258) LactateはIV型(FGFR1/3)とV型(VEGFR1-4) RTKsにも有効に作用して、IC50値が8-13 nMになりますが、InsR、EGFR、c-Met、EphA2、Tie2、IGF-1RとHER2に作用する効果が少し弱くなります。臨床4期。

  • AMG 925

    AMG 925 is a potent and orally bioavailable dual FLT3/CDK4 inhibitor with IC50 of 1 nM and 3 nM, respectively.

  • PX-478 2HCl

    PX-478 2HClは一種の経口活性をしている、選択性的なHIF-1α阻害剤です。臨床1期。

  • Defactinib (VS-6063, PF-04554878)

    Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.

  • Dovitinib (TKI-258, CHIR-258)

    Dovitinib (TKI258, CHIR258)は一種の多ターゲットRTK阻害剤で、無細胞試験でIII型(FLT3/c-Kit)に作用する効果が一番強くて、このIC50値が1 nM/2 nMです。同時に、Dovitinib (TKI258, CHIR258)はIV型(FGFR1/3)とV型(VEGFR1-4) RTKsにも有効に作用して、IC50値が8-13 nMになりますが、InsR、EGFR、c-Met、EphA2、Tie2、IGF-1RとHER2に作用する効果が少し弱くなります。臨床4期。

  • ENMD-2076

    ENMD-2076はオーロラ AとVEGFR(Flt3)を選択性的に作用して、IC50値が14 nMと1.86 nMにそれぞれ分かれますが、オーロラ Aに作用する選択性はオーロラBに作用する選択性より25倍が高くなって、VEGFR2/KDR、VEGFR3、FGFR1とFGFR2とPDGFRαに作用する効果が少し弱くなります。臨床2期。

    Features:Multi-target, anti-proliferative, pro-apoptotic activity, anti-angiogenic.

  • KW-2449

    KW-2449は一種の多ターゲット阻害剤です。KW-2449はFlt3に作用する効果が一番強くて、IC50値が6.6 nMになりますが、FGFR1、Bcr-Abl とオーロラ Aに適度に作用して、PDGFRβ、IGF-1RとEGFRを抑制する効果がありません。臨床1期。

    Features:Investigated as a FLT3 inhibitor in clinical trials, with others in early development.

  • Tandutinib (MLN518)

    Tandutinib (MLN518)は、FLT3、PDGFRとc-キットのATP競争的で非常に選択的な阻害剤で、 IC50がそれぞれ 0.22 μM、0.20 μM 、0.17 μMです。

  • Dovitinib (TKI-258) Dilactic Acid

    Dovitinib Dilactic acid (TKI258 Dilactic acid)は一種の「 Dovitinib」のDilactic acidで、一種の多ターゲットRTK阻害剤で、III型(FLT3/c-Kit)に作用する効果が一番強くて、このIC50値が1 nM/2 nMです。同時に、Dovitinib Dilactic acid (TKI258 Dilactic acid)はIV型(FGFR1/3)とV型(VEGFR1-4) RTKsにも有効に作用して、IC50値が8-13 nMになりますが、InsR、EGFR、c-Met、EphA2、Tie2、IGF-1RとHER2に作用する効果が少し弱くなります。臨床4期。

最近チェックしたアイテム

Tags: Quizartinib (AC220)を買う | Quizartinib (AC220)供給者 | Quizartinib (AC220)を購入する | Quizartinib (AC220)費用 | Quizartinib (AC220)生産者 | オーダーQuizartinib (AC220) | Quizartinib (AC220)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ